Foreign articles in which hadaclinic articles are cited

A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer

 

PubMed

Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy

the role of new biological drugs

Actually brain metastases may become resistant to this agentmore rapidly than primary lesions, but further clinical studies are required to confirm the use of gefitinib in this clinical setting

[2]. Thalidomide, an immune modulator with anti-angiogenic effects, should seem to have an interesting activity in brain metastases from NSCLC. Hada and Horiuchi [31] report a case

of lung cancer patient with brain metastases who had been treated with thalidomide, celceoxib and gemcitabine, after which brain metastases have almost completely disappeared. So, this combination may play an important role for patients with NSCLC and brain metastases.

 

Effects of cetuximab combined with afatinib on the expression of KDR and AQP1 in lung cancer

Invasion and metastasis of lung cancer is the main reason for the failure of treatment and death in patients with lung cancer. Tumor angiogenesis plays a vital role in the invasion and metastasis of tumors (Hada andHoriuchi, 2005).

 

 

A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine

 

PubMed

Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer

 

نقش مهارکننده‌های انتخابی آنزیم Cox-2 بر ژن HIF-1 alpha در سرطان ...

14 نفع بيماران ميباشد.

Aghili و همكاران، طي يك مطالعه كه تنها پژوهش باليني اثربخشي

سلكوكسيب بر روي سرطان كولوركتال در ايران است، به اين نتيجه

رسيدند كه در سرطان كولوركتال III-II Stage ،سلكوكسيب بههمراه

شيميدرماني و پرتودرماني باعث ارتقاي پاسخ كامل پاتولوژيكي

(response complete Pathological (در درمان نئوادجوانت (قبل از

يكي از دلايل پسرفت 15 جراحي براي كاهش حجم توده بدخيم) ميشود.

تومور در درمان با مهاركنندههاي انتخابي 2-Cox ،به اثرات ضد رگزايي

آن نسبت داده ميشود. Klenke و همكاران در يك مطالعه بر روي مدل

تجربي سرطان ريه نشان دادند كه سلكوكسيب باعث كاهش آنژيوژنز

همچنين Hada و همكاران، در سرطان لوزالمعده 16 توموري خواهد شد.

 17 به چنين نتيجه مشابهي دست يافته بودند.

 

Transcription Factor NF-ƒÈB: An Update on Intervention Strategies

Since NF-kappaB promotes angiogenesis and is involved in@cancer progression, it acts as a major target for the therapeutic@purposes. Various pharmacological substances like thalidomide, celecoxib, gemcitabine, cisplatin, doxorubicin,genistein, bortezomib, sulfasalazine and others either alone or in combination with radiotherapy or other pharmacological agents have already entered clinical studies and show promising results to treat various types of cancer (Hada and Mizutari 2004).

 

A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan

PubMed

A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma

Although there have been some recent reports of a potential synergistic effect of thalidomide and COX-2 inhibitors in the treatment of various solid tumors (40, 41), to date, there have been no prospective studies of this combination.

 

Stage II Trial of Capecitabine Joined Together with Thalidomide in Second-Line Medicine of Progressed Pancreatic Growth

Thalidomide has distinctive components of movement and action in diverse threatening tumors [12].

 

Antiangiogenic Cancer Therapy - CRC Press Book

Page 316

Celecoxib, thalidomide, and metronomic irinotecan have been successfully applied in pancreatic carcinoma.222

Reviews

— Joshua I. Greenberg, M.D. & David A. Cheresh, Ph.D., University of California, San Diego, La Jolla in The New England Journal of Medicine, July 2008

 

"It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject."

– In Anticancer Research, 2009, Vol. 29

                                                    

A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP

PubMed

LETTER TO THE EDITOR

Thalidomide in Primary Peritoneal Mesothelioma

Thalidomide has been increasingly used for its antiangiogenic property in several hematolymphoid and solid tumors. There needs to be further studies to establish the role of thalidomide in malignant mesothelioma.

 

Malignant mesothelioma

Other regimens like Vinorelbine and Gemcitabine, either alone or combined with platinum compounds are also used for unresectable disease.32 Among them the response rate of Vinorelbine alone is 24%34 whereas the Irinotecan35 and Gefinitib36 have not proved effective when used alone.

 

Drug Targets to Pro-Angiogenetic Factors with Special Reference to Primary Peritoneal Mesothelioma

 

Peritoneal Mesothelioma: A Review

 

Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities

PubMed

A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma

Although there have been some recent reports of a potential synergistic effect of thalidomide and COX-2 inhibitors in the treatment of various solid tumors (40, 41), to date, there have been no prospective studies of this combination.

 

Hyperthermic intraperitoneal chemotherapy as a new way of peritoneal metastases treatment